Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE trial: palbociclib added to fulvestrant after progression
jRCTs021180028Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of palbociclib in breast cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free survival (PFS). Started Jan 2018; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs021180028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180028.